Literature DB >> 12086979

Enhancement of apomorphine-induced penile erection in the rat by a selective alpha(1D)-adrenoceptor antagonist.

Hiroya Mizusawa1, Petter Hedlund, Johan Sjunnesson, Jorge D Brioni, James P Sullivan, Karl-Erik Andersson.   

Abstract

1. Effects of A-322312 (alpha(1B)-adrenoceptor (AR) antagonist), A-119637 (alpha(1D)-AR antagonist), prazosin (non-selective alpha(1)-AR antagonist), and yohimbine (alpha(2)-AR antagonist) were studied in rat corpus cavernosum (CC) and cavernous artery (Acc) preparations. Effects of intracavernous (i.c.) or intraperitoneal (i.p.) administration of alpha(1)-AR antagonists on apomorphine-induced erections were investigated. 2. A-119637 attenuated electrically induced contractions in isolated CC (-logIC(50); 8.12+/-0.15), and relaxed noradrenaline (NA)-contracted preparations by more than 90% at 10(-7) M. At the same concentration, the -logEC(50) value for NA in Acc was altered from 6.79+/-0.07 to 4.86+/-0.13. In the CC and Acc, prazosin similarly inhibited contractile responses. 3. Inhibitory effects of A-322312 (10(-7) M) in electrically activated CC were 32.3+/-5.1%, whereas no effect on concentration-response curves for NA was observed in the Acc. Yohimbine (10(-8) M and 10(-7) M), enhanced electrically-induced contractions in isolated CC by 20 to 50%. At 10(-6) M, inhibitory effects of yohimbine were obtained. 4. A-119637 (0.3 micromol kg(-1), i.p.) tripled the number of erections, and produced a 6 fold increase in the duration of apomorphine-induced erectile responses. A-322312, prazosin, or yohimbine did not enhance erections induced by apomorphine. None of the alpha(1)-AR antagonists significantly increased ICP upon i.c. administration. Decreases in blood pressure were seen with A-119637 and prazosin. 5. The present findings show that there is a functional predominance of the alpha(1D)-AR subtype in the rat erectile tissue, and that blockade of this receptor facilitates rat penile erection induced by a suboptimal dose of apomorphine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086979      PMCID: PMC1573401          DOI: 10.1038/sj.bjp.0704773

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

Review 1.  Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction.

Authors:  K E Andersson; C Stief
Journal:  World J Urol       Date:  2001-02       Impact factor: 4.226

Review 2.  Role of alpha adrenergic receptors in erectile function.

Authors:  A Traish; N N Kim; R B Moreland; I Goldstein
Journal:  Int J Impot Res       Date:  2000-03       Impact factor: 2.896

Review 3.  Pharmacology of penile erection.

Authors:  K E Andersson
Journal:  Pharmacol Rev       Date:  2001-09       Impact factor: 25.468

4.  Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien.

Authors:  W A Carroll; K B Sippy; T A Esbenshade; S A Buckner; A A Hancock; M D Meyer
Journal:  Bioorg Med Chem Lett       Date:  2001-05-07       Impact factor: 2.823

Review 5.  Vascular adrenoceptors: an update.

Authors:  S Guimarães; D Moura
Journal:  Pharmacol Rev       Date:  2001-06       Impact factor: 25.468

6.  Effects of intracavernous administration of selective antagonists of alpha(1)-adrenoceptor subtypes on erection in anesthetized rats and dogs.

Authors:  G Sironi; D Colombo; E Poggesi; A Leonardi; R Testa; O Rampin; J Bernabé; F Giuliano
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

7.  alpha-Melanocyte stimulating hormone and oxytocin induced penile erections, and intracavernous pressure increases in the rat.

Authors:  Hiroya Mizusawa; Petter Hedlund; Karl-Erik Andersson
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

Review 8.  Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction.

Authors:  I Goldstein
Journal:  Int J Impot Res       Date:  2000-03       Impact factor: 2.896

9.  Characterization of alpha-adrenoceptor subtypes in the corpus cavernosum of patients undergoing sex change surgery.

Authors:  M Goepel; S Krege; D T Price; G A Michelotti; D A Schwinn; M C Michel
Journal:  J Urol       Date:  1999-11       Impact factor: 7.450

10.  Key issues from the clinical trials of apomorphine SL.

Authors:  J P Heaton
Journal:  World J Urol       Date:  2001-02       Impact factor: 4.226

View more
  2 in total

Review 1.  Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.

Authors:  Debra A Schwinn; Claus G Roehrborn
Journal:  Int J Urol       Date:  2008-03       Impact factor: 3.369

2.  Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum.

Authors:  Kenshi Matsumoto; Masaki Yoshida; Karl-Erik Andersson; Petter Hedlund
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.